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Hypertension is a complex disease that affects a large proportion of adult population. Although approxi-
mately half of the inter-individual variance in blood pressure (BP) level is heritable, identiﬁcation of genes
responsible for its regulation has remained challenging. Genome-wide association study (GWAS) is a
novel approach to search for genetic variants contributing to complex diseases. We conducted GWAS for
three BP traits [systolic and diastolic blood pressure (SBP and DBP); hypertension (HYP)] in the
Kooperative Gesundheitsforschung in der Region Augsburg (KORA) S3 cohort (n 5 1644) recruited from gen-
eral population in Southern Germany. GWAS with 395 912 single nucleotide polymorphisms (SNPs) identiﬁed
an association between BP traits and a common variant rs11646213 (T/A) upstream of the CDH13 gene at
16q23.3. The initial associations with HYP and DBP were conﬁrmed in two other European population-
based cohorts: KORA S4 (Germans) and HYPEST (Estonians). The associations between rs11646213 and
†Kooperative Gesundheitsforschung in der Region Augsburg (KORA), the British Genetics of Hypertension study (BRIGHT), additional consortium
contributors are given in Supplementary Material.
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Advance Access published on March 20, 2009three BP traits were replicated in combined analyses (dominant model: DBP, P 5 5.55 3 10
–5, effect
–1.40 mmHg; SBP, P 5 0.007, effect –1.56 mmHg; HYP, P 5 5.30 3 10
28,O R5 0.67). Carriers of the minor
allele A had a decreased risk of hypertension. A non-signiﬁcant trend for association was also detected
with severe family based hypertension in the BRIGHT sample (British). The novel susceptibility locus,
CDH13, encodes for an adhesion glycoprotein T-cadherin, a regulator of vascular wall remodeling and angio-
genesis. Its function is compatible with the BP biology and may improve the understanding of the pathogen-
esis of hypertension.
INTRODUCTION
Hypertension is a common disease affecting 25% of the adult
population (1). Individuals with high blood pressure (BP) can
develop complications of the cardiovascular and kidney func-
tion. Continuously high BP is a complex physiological con-
dition where environmental and life-style factors such as
increased body mass, smoking, alcohol and salt consumption
as well as multiple genetic factors contribute to the develop-
ment of the disease (2). Twin studies have shown that up to
half of the inter-individual variance in BP level is heritable
(3). The heritability estimate for long-term average systolic
blood pressure (SBP) has been calculated to be 0.66 and for
diastolic blood pressure (DBP) 0.60 (4). A number of genes
and their mutations have been described to be responsible
for rare monogenetic traits that severely affect BP regulation
in families carrying these gene variants (5). Linkage scans
and candidate gene-based association studies have mapped a
large number (.160) of genomic regions to be potentially
associated with SBP, DBP or the clinical diagnosis of hyper-
tension (HYP) (6). In general, replication of the initially ident-
iﬁed associations has been challenging. Genome-wide
association studies (GWASs) are currently an alternative
methodology to search for novel genetic variants associated
with complex diseases (7). We conducted a GWAS for three
BP traits (SBP, DBP and HYP) in the Kooperative Gesund-
heitsforschung in der Region Augsburg (KORA) S3 epidemio-
logical cohort (n ¼ 1644) recruited from a general population
in Southern Germany. The association of one common single
nucleotide polymorphism (SNP) located upstream of the
CDH13 gene was replicated with HYP and DBP in two inde-
pendent study populations from Germany and Estonia. The
CDH13 gene encodes for a cell–cell adhesion glycoprotein
T-cadherin involved in vascular wall remodeling and angio-
genesis consistent with its potential role in BP regulation.
RESULTS
Genome-wide association study
The design of this study involved three stages: stage 1—
genome-wide analysis for the three BP traits in KORA S3, a
population-based cohort (Augsburg, Southern Germany) (8);
stage 2—replication in the same population, but in a different
independent cohort (KORA S4); stage 3—replication in two
further sample sets from European populations (HYPEST,
Estonians; BRIGHT, British) (Table 1; Supplementary
Material, Fig. S1). In stage 1, the KORA S3 sample of 1644
individuals was genotyped using the Affymetrix 500K Gene
Chips. A total of 395 912 SNPs were included for the associ-
ation analysis. These SNPs satisﬁed the following quality
control criteria: minor allele frequency (MAF)   1%, call
rate .93% and Hardy-Weinberg Equilibrium (HWE)
P-value .0.001. Associations were assessed by ﬁtting linear
or logistic regression to SBP and DBP or hypertension,
respectively. Although none of the detected P-values were
below the genome-wide signiﬁcance level of 1.26   10
27
after Bonferroni correction, the strength of some detected
associations was close to this level. The strongest associations
(P , 5   10
26; additive model) were detected between SBP
and six loci: 5q34 (rs12153297; P ¼ 3.46   10
27), 2p24
(rs10195618; P ¼ 6.42   10
27), 10p12 (rs7898888; P ¼
8.30   10
27), 17p11.2 (rs1242502; P ¼ 1.72   10
26),
10q22.1 (rs11814843; P ¼ 2.46   10
26) and 12q14.3
(rs11176419; P ¼ 4.94   10
26). These associations were
also reﬂected at the quantile–quantile (QQ)-plot of SBP
revealing a small excess of low P-values (Fig. 1). In addition,
three loci showed strong association with HYP: 16q23.3
(rs11646213; P ¼ 2.34   10
26, dominant model), 5q32.1
(rs2972345; P ¼ 3.17   10
26, additive model) and 18q22.3
(rs2052662; P ¼ 3.69   10
26, dominant model). Respective
QQ-plots are shown in Supplementary Material, Fig. S2. In
total, our genome-wide scan revealed 80 autosomal regions
associated with BP traits with P , 5.5   10
25 (Supplemen-
tary Material, Table S1). These regions contained either a
single SNP or a cluster of SNPs associated with SBP (n ¼
42), DBP (n ¼ 22) or HYP (n ¼ 16). Half of the 80 top
SNPs (n ¼ 41) exhibited association signal (P , 0.01) with
more than one of the BP phenotype.
Replication in population-based cohorts KORA S4
and HYPEST
To conﬁrm the associations found in GWAS and to minimize
the probability of identifying a false positive, we sought repli-
cation in three independent European samples. First, replica-
tion was attempted using a sample recruited separately from
the same population as in stage 1 with identical sampling
design (8) (n ¼ 1830; KORA S4 cohort; Germans; Table 1).
We included SNPs (n ¼ 77; 54 genomic regions) from stage
1 based on P-value, potential biological candidacy or location
near previously reported linkage peaks. All selected loci con-
tained more than one SNP with the evidence of association in
GWAS with tested BP traits (P , 10
23). In addition, SNPs
that appeared to be associated with more than one BP traits
were considered as higher priority to be followed up in the
replication stages (for a detailed description see Materials
and Methods section). Only a single SNP (rs11646213 at
Human Molecular Genetics, 2009, Vol. 18, No. 12 228916q23.3) was associated with all three BP traits (SBP, DBP
and HYP) in both the KORA S3 and KORA S4 samples
(Table 2; Supplementary Material, Tables S2–S4). In GWA
scan, evidence of association (P , 10
23) was also seen with
several other SNPs across a .1 Mb region, covering the
upstream and coding sequence of the CDH13 gene (Fig. 2).
Due to low linkage disequilibrium (LD), almost no correlation
is seen between the top SNP rs11646213 and the other associ-
ated markers in the close-by region. The associations of four
further SNPs selected for stage 2 (rs6784190, rs448559,
rs1994547 and rs9948310) were replicated with HYP and/or
SBP. The effect size estimates of the ﬁve SNPs have the
same sign and similar magnitude as in KORA S3. The loci
that failed replication and did not pass to stage 3 are shown
in Supplementary Material, Table S4.
A set of nine SNPs was carried on to the third stage and was
genotyped in another European population-based sample,
HYPEST (n ¼ 1823, Estonians; Table 1; Supplementary
Material, Tables S2–S3). Five SNPs were chosen based on
positive replication from stage 2 along with three neighboring
markers (for a detailed description see Materials and Methods
section). In addition, we included rs12731181 with the stron-
gest P-value (P ¼ 2.5   10
24, HYP) in stage 2, but seen
with opposite effects in KORA S3 and KORA S4 (Supplemen-
tary Material, Table S2). As in KORA S4, the most consistent
association signals in HYPEST were detected between
rs11646213 and DBP (P ¼ 0.017) as well as HYP (P ¼
0.048). The association with SBP was not conﬁrmed in
HYPEST (Table 2).
We performed a weighted meta-analysis (n ¼ 3665 for SBP,
DBP; n ¼ 1407 cases/2365 controls for HYP) to combine the
results in three population-based cohort samples (KORA S3,
S4 and HYPEST) (Table 2). Combined analysis improved
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Figure 1. Quantile–quantile plots of the x
2 statistic obtained from GWA
analysis for SBP under the additive genetic model in the KORA S3 500K
sample. The distribution of log10(P) of association tests is shown before
(black dots) and after (green dots) correction for population stratiﬁcation per-
formed by principal component analysis using the EIGENSOFT software (21).
A genomic control analysis led to an inﬂation factor (l) of 1.02.
2290 Human Molecular Genetics, 2009, Vol. 18, No. 12the statistical signiﬁcance of the association between
rs11646213 and DBP (P ¼ 5.55   10
–5, effect 21.40, SE
0.12, dominant model) as well as HYP (P ¼ 5.30   10
28,
OR ¼ 0.67, 95% CI: 0.58–0.77, dominant model). For both
phenotypes, the dominant model had a stronger support com-
pared with the additive effect model (Table 2). Meta-analysis
also replicated the initial association between rs11646213 and
SBP (P , 0.008) (Table 2). Carriers of the minor allele A
exhibited lower BP and reduced risk to develop hypertension
compared with the carriers of major allele homozygotes. In
KORA, carriers of the minor allele A (AAþAT) of
rs11646213 were measured in average 2.25 mmHg lower
SBP and 1.54 mmHg lower DBP compared with the major
allele TT homozygotes (Fig. 3A and B). The ‘protective’
effect of the minor allele increased after 50 years of age: car-
riers of the A allele were measured in average 3.24 and
2.08 mmHg lower SBP and DBP, respectively. In HYPEST,
the carriers of the A allele have an average 1.72 mmHg
lower DBP across all age groups (Fig. 3D).
In addition to rs11646213 (CDH13), the meta-analysis
across KORA S3, KORA S4 and HYPEST provided evidence
for tentative associations with BP for rs1994547 (TMEM16C),
rs6784190 (SLITRK3) and rs9948310, rs506038 (both
KCTD1) (Supplementary Material, Tables S2–S3). The
associations between rs1994547 and HYP (P ¼ 1.84   10
24,
OR ¼ 1.38) and between rs6784190 and SBP (P ¼ 3.34  
10
25, effect 1.78) reached P , 5   10
24 under the additive
model.
Replication in a family based hypertension case–control
sample BRIGHT
In BRIGHT, the original sampling design (9) allowed to test
association only with HYP, comparing cases from severely
hypertensive families matched with normotensive controls.
Among the nine SNPs genotyped in stage 3, the rs9948310
(18q11.2)locatedwithintheKCTD1generesultedinsigniﬁcant
association (P ¼ 5.70   10
24;O R ¼ 0.78, additive model)
(Supplementary Material, Table S2). However, this locus
needs further replication efforts as the effects in KORA S3
(P ¼ 3.07   10
22,O R ¼ 1.35) and KORA S4 (P ¼ 2.71  
10
22;O R ¼ 1.28) were in opposite direction. The SNP
rs11646213, which revealed consistent association with BP
traits in population-based cohorts KORA S3, KORA S4 and
HYPEST, showed also a non-signiﬁcant trend for association
with HYP in the BRIGHT cases from severely hypertensive
families (P ¼ 8.22   10
22,O R¼ 0.92, additive model; P ¼
1.41   10
21,O R¼ 0.90, dominant model).
DISCUSSION
Our genome-wide association screen with BP traits in the
KORA S3 cohort identiﬁed a common SNP rs11646213
(MAF ¼ 0.41), which revealed association signals with all
three BP traits (HYP P ¼ 2.34   10
26; DBP P ¼ 0.0034;
SBP P ¼ 0.02, dominant model) (Table 2). This SNP was
ranked among the top loci in GWAS (P , 5   10
26). Associ-
ations with HYP and DBP were replicated in two further
population-based cohort samples, representing western
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Human Molecular Genetics, 2009, Vol. 18, No. 12 2291(Germans, KORA S4) and eastern Europeans (Estonians,
HYPEST). In addition, a trend for association was observed
with severe family based hypertension in the British popu-
lation (BRIGHT).
The SNP rs11646213 is located 17.9 kb upstream of the
large cadherin 13 preprotein (CDH13) gene (1.2 Mb, 14
exons; Fig. 2). Although the association of the upstream
region of CDH13 with BP was not ultimatively conﬁrmed in
all sample sets of this study, the available published data on
this gene and its functions warrant further examination. Inde-
pendent evidence of the involvement of CDH13 in BP regu-
lation comes from GWAS conducted in another
population-based cohort, Framingham Heart Study using
Affy100K Gene Chip. In particular, the SNP rs3096277,
located within CDH13 intron 11 (1.12 Mb from
rs11646213), showed association P-values of P ¼ 9.90  
10
28 and P ¼ 1.40   10
24 with long-range SBP and DBP,
respectively (10). Furthermore, rs254340 located in the vicin-
ity of rs3096277 (29.9 kb) showed a borderline association
with SBP in the HYPEST sample (P ¼ 0.076) (Supplementary
Material, Table S3). Consistent with the evidence of these two
GWAS, the genomic region 16q23.1 has been also linked with
BP traits in linkage scans (Fig. 2) (11,12).
Although the detected variant explains a small fraction of the
total variation in BP level, the identiﬁed gene adapts well to the
BP biology. CDH13 encodes for a calcium-dependent cell–cell
adhesion glycoprotein T-cadherin that has the following
properties. It is predominantly expressed in nervous and
cardiovascular system, with the highest expression observed
in the aorta, the arteries and in the heart (13). T-cadherin inter-
acts in vascular endothelial and smooth muscle cells with two
different ligands, which both play an important role in cardio-
vascular physiology, low-density lipoproteins (14) and adipo-
nectins (15). It has been implicated as a regulator of vascular
wallremodelingandangiogenesis,andisup-regulatedinvascu-
lar endothelial cells under pathological conditions like within
atherosclerotic lesions (13,16).Consistent withthecontribution
of T-cadherin in tumor angiogenesis, the CDH13 gene has been
associatedwithdifferentcancertypes(lung,breastandprostate)
(17–19). All these features make this gene a promising candi-
date for BP regulation. Further ﬁne-mapping or re-sequencing
experiments will be required to clarify the signal of association
and to identify likely causal variants.
The three stages of the study provided supportive evidence
for the contribution of the identiﬁed locus to BP variability,
but the strength of replication varied among samples. This
may result from the phenotypic heterogeneity among sample
collections due to differences in study design and/or insufﬁ-
cient power to detect the modest associations. Recently, a
report by the family blood pressure program suggested the
effect of different study designs to explain the non-
replicability of the six most-signiﬁcant SNPs from the
WTCCC GWAS of essential hypertension (20). The KORA
S3, KORA S4 and HYPEST samples were recruited from
Figure 2. Genomic region of the rs11646213 associated with BP traits at 16q23.3. The upper part of the panel shows the chromosomal location of the SNP along
with a ﬂanking microsatellite D16S515 reported to be linked with BP traits (11,12). The middle part of the panel represents a plot of P-values from the genome-
wide scan (654 SNPs) in KORA S3 with HYP (open triangle; logistic regression), SBP and DBP (open circle and open square, linear regression), and from the
combined analysis of the population-based cohort samples KORA S3 (GWAS), KORA S4 and HYPEST under the dominant genetic model. The x-axis represents
the genomic position (NCBI build 35) and the y-axis shows –log10 (P-value). The lower part of the panel shows the gene content and linkage disequilibrium (LD)
pattern (pairwise r
2; KORA S3) of the genomic region. HYP, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; GWAS, genome-wide
association study.
2292 Human Molecular Genetics, 2009, Vol. 18, No. 12the general population and have multiple BP records available
over different periods of time. Thus, close phenotypic criteria
could be used for deﬁning samples entering association analy-
sis with SBP and DBP, as well as cases and controls in the
hypertension study. The MRC BRIGHT study provides a
resource of severely hypertensive families with a diagnosis
of hypertension (9). The combination of inheritance factors
responsible for familiar clustering of hypertension in the
British population may differ from the palette of genetic var-
iants contributing to BP regulation in the general populations
of Germany and Estonia. Also, population-speciﬁc genetic
variation may play a role in determining the power of the
association study. For example, the rs11646213 highlighted
in this study had lower MAF in the Estonian population com-
pared with the German population (Table 2), possibly weaken-
ing the power of the analysis with the HYPEST sample.
Despite the positive replication signals in two populations
and a trend for association in the third, we are aware of the
tentative nature of the detected association. One also has to
keep in mind alternative scenarios that the discovery
samples may have overestimated the effect size or the detected
signiﬁcant associations in study populations may still be by
chance alone.
In summary, our study provides evidence that GWAS scan
has a potential to identify novel genetic components contri-
buting to a complex multifactorial trait such as BP.
However, it highlights the importance to take into account
the potential heterogeneity in study design among discovery
and replication samples. In addition, population-speciﬁc gene
variants and/or gene–environment interactions may have a
contribution in increasing or reducing the risk to develop
hypertension. Thus, the ideal replication samples should be
recruited from a genetically close population, practicing
similar traditional life-style as the original study population.
The identiﬁcation of a novel susceptibility locus CDH13
contributing to BP determination encourages further
research to clarify the functional basis of the identiﬁed
association.
Figure 3. Mean and SEM of SBP (A and C) and DBP (B and D) among minor allele carriers and non-carriers of rs11646213 in combined KORA S3 þ S4
cohorts (total n ¼ 2497) and HYPEST samples (total n ¼ 1060) stratiﬁed by age. In KORA (A and B), the sample sizes in different age groups ranged from
351 to 739 for minor allele carriers (AAþAT) and from 189 to 367 for major allele homozygotes (TT). In HYPEST (C and D), the sample sizes in different
age groups ranged from 58 to 455 for minor allele carriers (AAþAT) and from 53 to 297 for major allele homozygotes (TT).
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Subjects and study design
An overview of the study design is shown in Supplementary
Material, Fig. S1. A detailed description of the recruitment
of the GWAS sample (KORA S3 cohort) and replication
samples KORA S4, HYPEST and BRIGHT is given below
and in Supplementary Material. All studies have been
approved by the local Ethics Committee and all participants
have given informed consent. All participants from the
KORA, the HYPEST and the BRIGHT studies are of white
European ancestry.
KORA S3 500K and replication sample KORA S4
The subjects in genome-wide (stage 1) and replication (stage
2) analyses were selected from KORA S3 and S4 surveys,
respectively. Both represent independent samples of unrelated
subjects from the general population from the Augsburg Area
(Southern Germany) recruited in 1994–1995 (S3) and 1999–
2001 (S4) (8). A fraction of the KORA S3 (n ¼ 4856) partici-
pants were followed up in 2003–2004 during the KORA F3
survey (n ¼ 2974). Subjects who participated in both S3 and
F3 surveys (n ¼ 1644, ages 25–69) were selected for genotyp-
ing on the Affymetrix 500K platform in the framework of the
KORA 500K consortium (http://epi.gsf.de/kora-gen/seiten/
kora500k_e.php). The standardized examinations applied in
both surveys have been described elsewhere (8). The charac-
teristics of both cohorts and determination of BP measure-
ments are given in Supplementary Material. GWAS with
SBP and DBP was conducted with BP data from the S3
survey, including only individuals not receiving BP lowering
medication (n ¼ 1017; Table 1). The distribution of SBP and
DBP measurements for the study group in the GWAS is
shown in Fig. S3. For case–control analysis, the groups of
hypertensives (1) (n ¼ 364) consist of: (i) individuals under
antihypertensive medication during both S3 and F3 surveys;
(ii) untreated subjects with SBP   160 mmHg and/or DBP  
100 mmHg (Grade 2 hypertension) in the S3 and F3 surveys
and (iii) untreated individuals with SBP   140 mmHg
(Grade 1 hypertension) in S3 that developed 10 years later
to Grade 2 or severe hypertension (F3 survey). Control sub-
jects (n ¼ 596) were selected to have optimal (,120/
80 mmHg) or normal (,130/85 mmHg) BP measured during
both S3 (original) and F3 (10 years later) surveys, and had
never been prescribed antihypertensive medication. We
excluded individuals with diabetes and/or with obesity
(BMI . 30 kg/m
2). In replication stage 2, we selected the
individuals from KORA S4 survey (full cohort n ¼ 4261)
that satisﬁed the same phenotype criteria as in GWAS with
S3 (n ¼ 1830; Table 1). A total of 1551 subjects entered the
association analysis with SBP and DBP. Case–control associ-
ation analysis (HYP) was performed with 447 hypertensives/
1119 normotensives.
HYPEST replication sample
The Estonian sample consists of unrelated subjects recruited
between 2004 and 2007 across Estonia in the framework of
the HYPEST sample collection (1823 individuals; recruitment
details in Supplementary Material). The aim of HYPEST
study is to ﬁnd hypertension risk factors in the Estonian popu-
lation. The recruited individuals have detailed epidemiological
data and a documented history of multiple SBP and DBP read-
ings (on average of 4.31 readings per individual) during mean
3.17 years. The selection of HYPEST individuals into the
replication stage followed as close as possible the phenotype
criteria used for KORA S3 and KORA S4 subjects. Associ-
ation analysis with SBP and DBP was performed using 1097
untreated individuals derived from the population-based
cohort consisting of long-term blood donors across Estonia
(Table 1). The distribution of BP values in the study group
is shown in Supplementary Material, Fig. S3. For binary
analysis with hypertension (HYP), cases (n ¼ 596) were
deﬁned as subjects with either BP readings  160/
100 mmHg based on the median of several measurements or
receiving antihypertensive therapy. Normotensive controls
(n ¼ 650; BP ,130/85 mmHg based on the mean of two inde-
pendent readings across mean 4.1 years or ,140/90 mmHg
based on the mean of more than or equal to three readings)
were selected from the population-based HYPEST cohort
among the subjects who have never been prescribed antihyper-
tensive treatment.
BRIGHT replication sample
The MRC British Genetics of Hypertension (BRIGHT) case–
control samples have been recruited across UK (http://
www.brightstudy.ac.uk). Case ascertainment and phenotyping
has been described elsewhere (9). Brieﬂy, cases originated
from severely hypertensive families (1700 sib-pairs and 800
families collected for transmission disequilibrium test) were
deﬁned as patients under antihypertensive treatment and
with BP readings  150/100 mmHg based on one reading
or  145/95 mmHg based on the mean of three readings.
Healthy normotensive controls (n ¼ 2000; BP ,140/
90 mmHg, no antihypertensive medication and no diagnosed
diseases) were recruited by matching age, sex and geographi-
cal distribution across UK. In replication stage 3b, 493 unre-
lated BRIGHT cases and 2000 controls were genotyped. For
association analysis with HYP, we also included BRIGHT
hypertensive cases genotyped in the framework of the
WTCCC (7). The association analysis (cases n ¼ 2401/con-
trols n ¼ 1969) was performed with subjects with BMI   35
and no diabetes (Table 1). Since BRIGHT cases (severe hyper-
tension; all subjects treated with antihypertension medication)
were collected as extremes, we were unable to test associ-
ations with SBP and DBP.
KORA S3 genotyping and SNP quality
Genotyping for KORA S3 500K was performed using the
Affymetrix Gene Chip Human Mapping 500K Array Set con-
sisting of two chips (Sty I and Nsp I). Genotyping experiments
were carried out according to the manufacturer’s instructions,
and the genotypes were determined using BRLMM clustering
algorithm. Genotyping laboratory experiments, call of geno-
types and genotyping quality control are described in detail
elsewhere (http://epi.gsf.de/kora-gen/seiten/kora500k_e.php).
We excluded SNPs with signals of unreliable genotyping
2294 Human Molecular Genetics, 2009, Vol. 18, No. 12quality (call rate ,93%), deviation from HWE (P , 0.001)
and rare SNPs (MAF , 1%). Exclusion details are given in
Supplementary Material. The number of autosomal SNPs
entering the statistical analysis was 395 912.
SNP selection for replication
SNPs selected to be genotyped in the replication stage 2 (in
total n ¼ 77; Supplementary Material, Tables S2–S4) satisﬁed
one of the following conditions: (i) SNPs with the strongest
evidence for association (n ¼ 4; P-value , 10
26); (ii) SNPs
with P-value , 5.5   10
25 from regions revealing multiple
associations (n ¼ 19) and/or near reported linkage peaks
(n ¼ 15) or (iii) exonic SNPs (n ¼ 4; P-value , 10
23); (iv)
signiﬁcant SNPs exhibiting overlapping association signals
with SBP, DBP and HYP and/or close to potential BP candi-
date genes (n ¼ 33; P-value , 10
22). Top SNPs located
within or in the vicinity (+100 kb) of a known copy
number variation regions (n ¼ 18; Supplementary Material,
Table S1) were not followed up due to the inability to dis-
tinguish between true and spurious associations.
In stage 3, we selected SNPs, which reached signiﬁcant
(n ¼ 6 SNPs; P , 0.05) or borderline P-values (n ¼ 1; P ,
0.07), in association tests with SBP, DBP or HYP in stage 2
(Supplementary Material, Tables S2 and S3). In addition, we
carried on two SNPs within the CDH13 gene, rs3784990
and rs254340. Despite negative replication in KORA S4,
these SNPs were considered for further testing in other popu-
lations as they are ﬂanking rs3096277 with prior evidence for
association with BP from Framinghm Heart Study 100K
GWAS (10). In GWAS sample KORA S3, the marker
rs3784990 was among top SNPs (HYP, additive model, P ¼
2.21   10
25) and rs254340 showed association signals with
SBP and DBP (P , 9   10
23) (Supplementary Material,
Table S1).
SNP genotyping in the replication samples
Stage 2 genotyping (KORA S4 cohort, n ¼ 1830) of 74 SNPs
was performed using the iPLEX assay (Sequenom; primers are
given in Supplementary Material, Table S5). Three SNPs
(rs11646213, rs254340 and rs3784990) with insufﬁcient per-
formance of iPLEX assay were genotyped using 50-nuclease
allelic discrimination (Taqman) assay (Applied Biosystems).
Stage 3 genotyping was performed using the KASPar chem-
istry, a competitive allele-speciﬁc PCR SNP genotyping
system using ﬂuorescence resonance energy transfer quencher
cassette oligos (the Genotyping Unit of the William Harvey
Research Institute; call rate .97%). All SNPs genotyped
were in HWE, and overall genotyping call rate was .97%
for HYPEST and .95% for BRIGHT samples (Supplemen-
tary Material, Table S6). Replication experiments are detailed
in Supplementary Material.
Statistical analysis of genetic effects
The possible effect of population stratiﬁcation in the KORA
S3 500K sample was assessed using the EIGENSOFT soft-
ware (21,22) as described (23). A principal component analy-
sis showed a negligible effect of population stratiﬁcation
(Fig. 1; Supplementary Material, Fig. S2). The genomic
control analysis (24) led to an inﬂation factor (l) of 1.02
and 1.05 for quantitative (SBP) and case–control (HYP) phe-
notypes, respectively.
The signiﬁcance of the locus-trait associations was tested,
and odds ratios/effect sizes and conﬁdence interval were
obtained by ﬁtting linear (with SBP and DBP) and logistic
(with HYP) regressions implemented in the PLINK software
(25). All analyses were adjusted for age and sex. In all study
stages, the association analyses were performed under additive
and dominant genetic models. Additive genetic models
assume a trend per copy of the minor allele to contribute to
SBP and DBP measurements on genotype categories,
whereas dominant genetic models assume that heterozygotes
have the same increased risk as minor homozygous genotypes.
We considered the Bonferroni (P ¼ 0.05/395912¼1.26  
10
27) threshold that takes into account that multiple hypoth-
eses test are being performed. In addition, we estimated the
effective number of independent test performed genome-wide
as the number of tagging SNPs. The tagging SNPs were
selected using Carlson et al. (26) method implemented using
in-house ‘perl’ code (threshold r
2 . 0.4). The estimated
number of effective tests was 141 870, which gives the signiﬁ-
cance level after Bonferroni correction of P ¼ 3.52   10
27
(P ¼ 0.05/141870). LD structure of the highlighted regions
was visualized using HAPLOVIEW (27). Results were com-
bined in a meta-analysis using the inverse-variance method
under ﬁxed-effects models using the R software.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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